Clinical trial · Interventional
Use of Topotecan in Patients With Refractory Acute Leukemia
Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
NCT00100477CI-TRIAL-00012276completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Arm 1
- interventionNames
- Drug: Topotecan
- Drug: Mitozantrone
- Drug: Etoposide
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: Patients in the following disease categories will be considered eligible for this study: * Any acute leukemia beyond an initial attempt to induce a remission or after relapse * Chronic Myelogenous Leukemia in Blast Phase * Refractory Multiple Myeloma * Refractory non-Hodgkin's and Hodgkin's Lymphoma * Patients must be more than 14 days beyond prior myelotoxic chemotherapy * Several other eligibility criteria apply. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.